Literature DB >> 7461038

Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection.

K Fuxe, K Andersson, V Locatelli, L F Agnati, T Hökfelt, L Skirboll, V Mutt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7461038     DOI： 10.1016/0014-2999(80)90521-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


× No keyword cloud information.
  15 in total

1.  Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies.

Authors:  C A Tamminga; R L Littman; L D Alphs; T N Chase; G K Thaker; A M Wagman
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia.

Authors:  E Peselow; B Angrist; A Sudilovsky; J Corwin; J Siekierski; F Trent; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Neurotensin and cholecystokinin coexistence within neurons of the ventral mesencephalon: projections to forebrain.

Authors:  K B Seroogy; A Mehta; J H Fallon
Journal:  Exp Brain Res       Date:  1987       Impact factor: 1.972

Review 4.  A controlled study of Tourette syndrome. VII. Summary: a common genetic disorder causing disinhibition of the limbic system.

Authors:  D E Comings
Journal:  Am J Hum Genet       Date:  1987-11       Impact factor: 11.025

5.  Effects of ceruletide on the dopamine receptor-adenylate cyclase system in striatum and frontal cortex of rats chronically treated with haloperidol.

Authors:  Y Hatta; S Hatta; T Saito
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Effects of ceruletide on perioral movements and the dopamine receptor-adenylate cyclase system in rats chronically treated with fluphenazine.

Authors:  T Ashizawa; T Saito; N Takahata
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

7.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

8.  Involvement of cholecystokinin receptors in the control of striatal dopamine autoreceptors.

Authors:  S Tanganelli; K Fuxe; G von Euler; L F Agnati; L Ferraro; U Ungerstedt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

9.  Intracerebroventricular administration of cholecystokinin inhibits the activity of the dopaminergic and serotoninergic systems of the brain.

Authors:  E E Vasar; L K Ryago
Journal:  Neurosci Behav Physiol       Date:  1985 May-Jun

10.  Tyrosine hydroxylase and cholecystokinin mRNA levels in the substantia nigra, ventral tegmental area, and locus ceruleus are unaffected by acute and chronic haloperidol administration.

Authors:  S L Cottingham; D Pickar; T K Shimotake; P Montpied; S M Paul; J N Crawley
Journal:  Cell Mol Neurobiol       Date:  1990-03       Impact factor: 5.046
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.